Literature DB >> 17201731

The specific free radical scavenger edaravone suppresses bleomycin-induced acute pulmonary injury in rabbits.

Toshihiro Asai1, Yasushi Ohno, Shinya Minatoguchi, Norihiko Funaguchi, Hideyuki Yuhgetsu, Masahiro Sawada, Genzou Takemura, A Komada, Takako Fujiwara, Hisayoshi Fujiwara.   

Abstract

1. Intratracheal instillation of bleomycin induces a condition in rabbits that serves as a useful model of human pulmonary fibrosis. Bleomycin-induced production of reactive oxygen species leads to acute lung inflammation and induction of apoptosis, which is followed by pulmonary fibrosis at a later chronic stage. In the present study, we tested whether edaravone, a free radical scavenger, would suppress bleomycin-induced acute pulmonary inflammation. 2. Rabbits were divided into three groups (n = 10 in each): (i) a bleomycin-treated group, which received intratracheal instillation of 2 mg/kg bleomycin; (ii) a bleomycin + edaravone group, which received a 10 day regimen of daily intravenous injections of edaravone (3 mg/kg per day) beginning 3 days before bleomycin instillation; and (iii) a saline control group. Rabbits were killed for analysis 7 days after bleomycin administration. 3. In lung tissues from the bleomycin-treated group, marked infiltration of inflammatory cells, consisting mainly of lymphocytes, neutrophils and eosinophils, was observed. In addition, significantly increased numbers of TUNEL-positive (apoptotic) and transforming growth factor-beta-positive cells were seen. All these effects were significantly attenuated by treatment with edaravone. 4. The findings of the present study suggest that edaravone may be useful in the prevention of acute lung injury resulting from the production of reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17201731     DOI: 10.1111/j.1440-1681.2007.04528.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  6 in total

Review 1.  Pharmacological antioxidant strategies as therapeutic interventions for COPD.

Authors:  Irfan Rahman
Journal:  Biochim Biophys Acta       Date:  2011-11-09

2.  Beyond free radical scavenging: Beneficial effects of edaravone (Radicut) in various diseases (Review).

Authors:  Kiyoshi Kikuchi; Nobuyuki Takeshige; Naoki Miura; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Kei Miyata; Chiemi Kikuchi; Narumi Iida; Hisaaki Uchikado; Naohisa Miyagi; Naoto Shiomi; Terukazu Kuramoto; Ikuro Maruyama; Motohiro Morioka; Ko-Ichi Kawahara
Journal:  Exp Ther Med       Date:  2011-09-20       Impact factor: 2.447

3.  Survivin is involved in the anti-apoptotic effect of edaravone in PC12 cells.

Authors:  Xue-Yuan Liu; Ling-Ling Yao; Yu-Juan Chen; Bei-Bei Tao; Yong-Chun Yu; Wei-Hong Bian; Jing Yu; Yong-Gang Wang
Journal:  Mol Cell Biochem       Date:  2009-02-18       Impact factor: 3.396

4.  Serine/threonine kinase-protein kinase B and extracellular signal-regulated kinase regulate ventilator-induced pulmonary fibrosis after bleomycin-induced acute lung injury: a prospective, controlled animal experiment.

Authors:  Li-Fu Li; Shuen-Kuei Liao; Chung-Chi Huang; Ming-Jui Hung; Deborah A Quinn
Journal:  Crit Care       Date:  2008-08-09       Impact factor: 9.097

5.  Inhibition of fibrosis and inflammation by triple therapy with pirfenidone, edaravone and erythropoietin in rabbits with drug-induced lung injury: comparison of CT imaging and pathological findings.

Authors:  Shobu Watanabe; Norihisa Nitta; Akinaga Sonoda; Ayumi Nitta-Seko; Shinichi Ohta; Keiko Tsuchiya; Hideji Otani; Yuki Tomozawa; Yukihiro Nagatani; Kenichi Mukaisho; Masashi Takahashi; Kiyoshi Murata
Journal:  Exp Ther Med       Date:  2013-09-18       Impact factor: 2.447

6.  Effect of early treatment with transcutaneous electrical diaphragmatic stimulation (TEDS) on pulmonary inflammation induced by bleomycin.

Authors:  Laisa A Santos; Carlos A Silva; Maria L O Polacow
Journal:  Braz J Phys Ther       Date:  2013-11-14       Impact factor: 3.377

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.